Log In Sign up
The largest database of trusted experimental protocols

Human calprotectin elisa kit

Manufactured by Hycult Biotech
Visit Supplier
Sourced in Germany

The Human Calprotectin ELISA kit is a quantitative in vitro diagnostic assay designed for the measurement of calprotectin levels in human samples. Calprotectin is a biomarker associated with various inflammatory conditions. The kit utilizes the enzyme-linked immunosorbent assay (ELISA) principle to detect and quantify calprotectin concentrations in the tested samples.

Automatically generated - may contain errors

Lab products found in correlation

Quant it picogreen dsdna kit, by Thermo Fisher Scientific (4 mentions) Cell death detection elisaplus kit, by Roche (4 mentions) Human mpo elisa kit, by Abnova (3 mentions) Human pmn elastase elisa kit, by Abcam (1 mentions) Human il 6 high sensitivity elisa kit, by Diaclone (1 mentions) Dxh 900, by Beckman Coulter (1 mentions)

4 protocols using human calprotectin elisa kit

1

Quantification of NET Markers in Plasma

Cited 2 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
Different markers of NETs were quantified in the plasma sample obtained before surgery, following the strategy addressed in previous studies (11 (link)–13 (link)), according to manufacturer´s instructions. Namely, cell-free DNA (cfDNA, Quant-iT PicoGreen dsDNA kit, Life Technologies, Eugene, OR, USA), nucleosomes (Cell Death Detection ELISAPLUS kit, Roche, Mannheim, Germany), calprotectin (Human Calprotectin ELISA kit, Hycult Biotech, Uden, The Netherlands), myeloperoxidase (MPO, Human MPO ELISA kit, Abnova, Taoyuan, Taiwan) and neutrophil elastase (NE, PMN Elastase Human ELISA Kit, Abcam, Cambridge, UK).
As inflammation marker, we quantified interleukin 6 (IL-6) (Human IL-6 High Sensitivity ELISA Kit, Diaclone, Besançon, France) following manufacturer´s instructions.
Herranz R., Oto J., Hueso M., Plana E., Cana F., Castaño M., Cordón L., Ramos-Soler D., Bonanad S., Vera-Donoso C.D., Martínez-Sarmiento M, & Medina P. (2023). Bladder cancer patients have increased NETosis and impaired DNaseI-mediated NET degradation that can be therapeutically restored in vitro. Frontiers in Immunology, 14, 1171065.
+ Open protocol
+ Expand
2

Quantifying Neutrophil Activation Markers

Cited 3 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
Different markers of neutrophil activation were quantified in the plasma sample obtained before surgery, following the strategy addressed in previous studies [51 (link),52 (link),53 (link),54 (link),55 (link),56 (link),62 (link)] and following manufacturer´s instructions. These markers were: cfDNA (Quant-iT PicoGreen dsDNA kit, Life Technologies, Eugene, OR, USA) and nucleosomes (Cell Death Detection ELISAPLUS kit, Roche, Mannheim, Germany) as markers of the neutrophil nuclear content released upon NETosis; calprotectin (Human Calprotectin ELISA kit, Hycult Biotech, Uden, The Netherlands) as marker of cytoplasmic content; and MPO (Human MPO ELISA kit, Abnova, Taoyuan, Taiwan) as marker of granules content, both released upon neutrophil activation by different mechanisms.
Oto J., Plana E., Solmoirago M.J., Fernández-Pardo Á., Hervás D., Cana F., España F., Artoni A., Bucciarelli P., Carrabba G., Navarro S., Merati G, & Medina P. (2020). microRNAs and Markers of Neutrophil Activation as Predictors of Early Incidental Post-Surgical Pulmonary Embolism in Patients with Intracranial Tumors. Cancers, 12(6), 1536.
+ Open protocol
+ Expand
3

Neutrophil Activation Markers Evaluation

Cited 2 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
Different markers of neutrophil activation were measured in every plasma sample obtained during follow-up from the 32 patients studied herein, following the strategy addressed in previous studies [51 (link),52 ,53 (link),54 (link),55 (link),56 (link),57 (link)]. Cell-free DNA (cfDNA; Quant-iT PicoGreen dsDNA kit, Life Technologies, Eugene, OR, USA) and nucleosomes (Cell Death Detection ELISAPLUS kit, Roche, Mannheim, Germany) were measured as markers of the nuclear content of neutrophils released by neutrophils upon NETosis. Calprotectin (Human Calprotectin ELISA kit, Hycult Biotech, Uden, The Netherlands) was measured as a marker of cytoplasmic content and MPO (Human MPO ELISA kit, Abnova, Taoyuan, Taiwan) as a marker of the content of neutrophil granules, were both released upon neutrophil activation by different mechanisms. In all cases the experiments were performed following the manufacturer’s instructions.
Oto J., Navarro S., Larsen A.C., Solmoirago M.J., Plana E., Hervás D., Fernández-Pardo Á., España F., Kristensen S.R., Thorlacius-Ussing O, & Medina P. (2020). MicroRNAs and Neutrophil Activation Markers Predict Venous Thrombosis in Pancreatic Ductal Adenocarcinoma and Distal Extrahepatic Cholangiocarcinoma. International Journal of Molecular Sciences, 21(3), 840.
+ Open protocol
+ Expand
4

Quantifying NETosis Biomarkers in Plasma

Cited 3 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
Plasma neutrophil count was assessed in DXH900 (Beckman Coulter). Five biomarkers of NETosis were quantified in both biofluids following protocols already employed in our group (33 (link)–35 (link)). Specifically, cell-free DNA (cfDNA) (Quant-iT PicoGreen dsDNA kit, Life Technologies) and DNA-nucleosomes complexes (Cell Death Detection ELISAPLUS kit, Roche) were measured as markers of neutrophil nuclear content; calprotectin (Human Calprotectin ELISA kit, Hycult Biotech) was measured as marker of cytoplasmic content and MPO (Human MPO ELISA kit, Abnova) as marker of granular content. Finally, DNA- citH3 complexes were also measured, as previously described (36 (link)).
Tomás-Pérez S., Oto J., Aghababyan C., Herranz R., Cuadros-Lozano A., González-Cantó E., Mc Cormack B., Arrés J., Castaño M., Cana F., Martínez-Fernández L., Santonja N., Ramírez R., Herreros-Pomares A., Cañete-Mota S., Llueca A., Marí-Alexandre J., Medina P, & Gilabert-Estellés J. (2023). Increased levels of NETosis biomarkers in high-grade serous ovarian cancer patients’ biofluids: Potential role in disease diagnosis and management. Frontiers in Immunology, 14, 1111344.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!